Literature DB >> 22498736

PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential.

Wei-Jong Shia1, Akiko J Okumura, Ming Yan, Ali Sarkeshik, Miao-Chia Lo, Shinobu Matsuura, Yukiko Komeno, Xinyang Zhao, Stephen D Nimer, John R Yates, Dong-Er Zhang.   

Abstract

Fusion protein AML1-ETO, resulting from t(8;21) translocation, is highly related to leukemia development. It has been reported that full-length AML1-ETO blocks AML1 function and requires additional mutagenic events to promote leukemia. We have previously shown that the expression of AE9a, a splice isoform of AML1-ETO, can rapidly cause leukemia in mice. To understand how AML1-ETO is involved in leukemia development, we took advantage of our AE9a leukemia model and sought to identify its interacting proteins from primary leukemic cells. Here, we report the discovery of a novel AE9a binding partner PRMT1 (protein arginine methyltransferase 1). PRMT1 not only interacts with but also weakly methylates arginine 142 of AE9a. Knockdown of PRMT1 affects expression of a specific group of AE9a-activated genes. We also show that AE9a recruits PRMT1 to promoters of AE9a-activated genes, resulting in enrichment of H4 arginine 3 methylation, H3 Lys9/14 acetylation, and transcription activation. More importantly, knockdown of PRMT1 suppresses the self-renewal capability of AE9a, suggesting a potential role of PRMT1 in regulating leukemia development.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22498736      PMCID: PMC3367897          DOI: 10.1182/blood-2011-04-347476

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  52 in total

1.  MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function.

Authors:  Chi Wai So; Michael L Cleary
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

2.  Multiple regions of ETO cooperate in transcriptional repression.

Authors:  D Hildebrand; J Tiefenbach; T Heinzel; M Grez; A B Maurer
Journal:  J Biol Chem       Date:  2001-01-09       Impact factor: 5.157

3.  Protein-arginine methyltransferase 1 suppresses megakaryocytic differentiation via modulation of the p38 MAPK pathway in K562 cells.

Authors:  Yuan-I Chang; Wei-Kai Hua; Chao-Ling Yao; Shiaw-Min Hwang; Yi-Chi Hung; Chih-Jen Kuan; Jiun-Shyang Leou; Wey-Jinq Lin
Journal:  J Biol Chem       Date:  2010-05-04       Impact factor: 5.157

4.  Large-scale analysis of the yeast proteome by multidimensional protein identification technology.

Authors:  M P Washburn; D Wolters; J R Yates
Journal:  Nat Biotechnol       Date:  2001-03       Impact factor: 54.908

5.  AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations.

Authors:  Y Yuan; L Zhou; T Miyamoto; H Iwasaki; N Harakawa; C J Hetherington; S A Burel; E Lagasse; I L Weissman; K Akashi; D E Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

6.  PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells.

Authors:  J Tang; A Frankel; R J Cook; S Kim; W K Paik; K R Williams; S Clarke; H R Herschman
Journal:  J Biol Chem       Date:  2000-03-17       Impact factor: 5.157

7.  ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.

Authors:  J M Amann; J Nip; D K Strom; B Lutterbach; H Harada; N Lenny; J R Downing; S Meyers; S W Hiebert
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

8.  Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor.

Authors:  H Wang; Z Q Huang; L Xia; Q Feng; H Erdjument-Bromage; B D Strahl; S D Briggs; C D Allis; J Wong; P Tempst; Y Zhang
Journal:  Science       Date:  2001-05-31       Impact factor: 47.728

9.  Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation.

Authors:  Cristina G de Guzman; Alan J Warren; Zheng Zhang; Larry Gartland; Paul Erickson; Harry Drabkin; Scott W Hiebert; Christopher A Klug
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

10.  Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia.

Authors:  Masakazu Higuchi; Darin O'Brien; Parasakthy Kumaravelu; Noel Lenny; Eng-Juh Yeoh; James R Downing
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

View more
  62 in total

Review 1.  Small Molecule Inhibitors of Protein Arginine Methyltransferases.

Authors:  Hao Hu; Kun Qian; Meng-Chiao Ho; Y George Zheng
Journal:  Expert Opin Investig Drugs       Date:  2016-02-16       Impact factor: 6.206

2.  AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation.

Authors:  X N Gao; F Yan; J Lin; L Gao; X L Lu; S C Wei; N Shen; J X Pang; Q Y Ning; Y Komeno; A L Deng; Y H Xu; J L Shi; Y H Li; D E Zhang; C Nervi; S J Liu; L Yu
Journal:  Leukemia       Date:  2015-03-02       Impact factor: 11.528

3.  Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment.

Authors:  Krittiya Korphaisarn; Chao-Kai Chou; Wei-Ya Xia; Callisia N Clarke; Riham Katkhuda; Jennifer S Davis; Kanwal Ps Raghav; Hsin-Wei Liao; Ji-Yuan Wu; David G Menter; Dipen M Maru; Mien-Chie Hung; Scott Kopetz
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

4.  New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.

Authors:  Jian Li; Chun Guo; Nickolas Steinauer; Jinsong Zhang
Journal:  Front Biol (Beijing)       Date:  2016-09-03

Review 5.  Posttranslational modifications of RUNX1 as potential anticancer targets.

Authors:  S Goyama; G Huang; M Kurokawa; J C Mulloy
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

6.  Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.

Authors:  Chun Guo; Jian Li; Nickolas Steinauer; Madeline Wong; Brent Wu; Alexandria Dickson; Markus Kalkum; Jinsong Zhang
Journal:  J Biol Chem       Date:  2020-02-18       Impact factor: 5.157

7.  FLT3-ITD gets by with a little help from PRMT1.

Authors:  Kira Gritsman
Journal:  Blood       Date:  2019-08-08       Impact factor: 22.113

Review 8.  Inhibitors of Protein Methyltransferases and Demethylases.

Authors:  H Ümit Kaniskan; Michael L Martini; Jian Jin
Journal:  Chem Rev       Date:  2017-03-24       Impact factor: 60.622

Review 9.  Role of RUNX1 in hematological malignancies.

Authors:  Raman Sood; Yasuhiko Kamikubo; Paul Liu
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

10.  Arginine methylation of SMAD7 by PRMT1 in TGF-β-induced epithelial-mesenchymal transition and epithelial stem-cell generation.

Authors:  Yoko Katsuno; Jian Qin; Juan Oses-Prieto; Hongjun Wang; Olan Jackson-Weaver; Tingwei Zhang; Samy Lamouille; Jian Wu; Alma Burlingame; Jian Xu; Rik Derynck
Journal:  J Biol Chem       Date:  2018-06-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.